We thank Bruce Quinn, MD, PhD (Bruce Quinn Associates LLC), for his insights, and Oliver Febbo, student intern (Urban School), for his assistance in data abstraction. Dr. Quinn and Mr. Febbo were not paid for their contributions.
Centers for Medicare & Medicaid Services. Decision memo for next generation sequencing (NGS) for Medicare beneficiaries with advanced cancer (CAG-00450N). Accessed March 2, 2020. Available at: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=290&DocID=CAG-00450N&bc=AAAAAAAAQAAA&
Chin RI, Chen K, Usmani A, . Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA). Mol Diagn Ther 2019;23:311–331.
Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med 2018;379:1754–1765.
Duréndez-Sáez E, Azkárate A, Meri M, . New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA. J Thorac Dis 2017;9(Suppl 13):S1332–1345.
Karlovich CA, Williams PM. Clinical applications of next-generation sequencing in precision oncology. Cancer J 2019;25:264–271.
Marmarelis M, Thompson JC, Aggarwal C, . Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. Ann Transl Med 2017;5:380.
Merker JD, Oxnard GR, Compton C, . Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol 2018;36:1631–1641.
IJzerman MJ, Berghuis AMS, de Bono JS, . Health economic impact of liquid biopsies in cancer management. Expert Rev Pharmacoecon Outcomes Res 2018;18:593–599.
Oellerich M, Christenson RH, Beck J, . Plasma EGFR mutation testing in non-small cell lung cancer: a value proposition. Clin Chim Acta 2019;495:481–486.
Douglas MP, Parker SL, Trosman JR, . Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genet Med 2019;21:152–160.
Phillips KA, Deverka PA, Trosman JR, . Payer coverage policies for multigene tests. Nat Biotechnol 2017;35:614–617.
Trosman JR, Weldon CB, Kelley RK, . Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw 2015;13:311–318.
Trosman JR, Weldon CB, Slavotinek A, . Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med 2020;22:283–291.
- Search Google Scholar
- Export Citation
)| false . , Trosman JR , Weldon CB , Slavotinek A Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med 2020; 22: 283– 291. 31501586 10.1038/s41436-019-0650-7
Slavin TP, Banks KC, Chudova D, . Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing [published online October 19, 2018]. J Clin Oncol, doi:10.1200/JCO.18.00328:JCO1800328
- Search Google Scholar
- Export Citation
)| false . , Slavin TP , Banks KC , Chudova D Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing [published online October 19, 2018]. J Clin Oncol, doi: 10.1200/JCO.18.00328:JCO1800328
Centers for Medicare & Medicare Services. Advanced search. Accessed June 5, 2020. Available at: https://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx
Centers for Medicare & Medicaid Services. SUPERSEDED local coverage determination (LCD): MolDX: plasma-based genomic profiling in solid tumors (L38043). Accessed on June 5, 2020. Available at: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38043&ver=3&bc=AAAAAAAAgAAA&
Trosman JR, Douglas MP, Liang SY, . Insights from a temporal assessment of increases in U.S. private payer coverage of tumor sequencing from 2015 to 2019. Value Health 2020;23:551–558.
Trosman JR, Van Bebber SL, Phillips KA. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract 2010;6:238–242.
Trosman JR, Weldon CB, Gradishar WJ, . From the past to the present: insurer coverage frameworks for next-generation tumor sequencing. Value Health 2018;21:1062–1068.
Trosman JR, Weldon CB, Douglas MP, . Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the Precision Medicine Initiative. J Natl Compr Canc Netw 2017;15:219–228.